# Intranasal Ketamine and Fracture Reduction in Pediatric Emergencies (KETAPED)

> **NCT03525821** · PHASE3 · COMPLETED · sponsor: **Fondation Lenval** · enrollment: 9 (actual)

## Conditions studied

- Fractures, Closed

## Interventions

- **DRUG:** Ketamine Hydrochloride

## Key facts

- **NCT ID:** NCT03525821
- **Lead sponsor:** Fondation Lenval
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-05
- **Primary completion:** 2020-09-13
- **Final completion:** 2020-09-13
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2020-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03525821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03525821, "Intranasal Ketamine and Fracture Reduction in Pediatric Emergencies (KETAPED)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03525821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*